PRINCETON, N.J., June 27, 2025 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR ...

A new fight is brewing over the Medicare drug price negotiation program after the Trump administration proposed to consider ...

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels ...

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

PRINCETON, N.J., June 27, 2025 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T ...

The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a ...

Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell therapies. Read more here.

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

Bristol Myers Squibb (NYSE:BMY) announced that the U.S. FDA has approved several label updates for its cancer therapies, Breyanzi and Abecma, which could help the company widen access to the two CAR-T ...

Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) for the ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy ...